Nephrology Advances in 2025: FDA Approvals and Clinical Breakthroughs Transform Kidney Disease Treatment
核心洞察
The FDA approved multiple breakthrough therapies in 2025, including semaglutide for chronic kidney disease (搜索), atrasentan for IgA nephropathy (搜索), and pegcetacoplan for C3 glomerulopathy (搜索), marking a shift toward precision-driven nephrology care.
IgA nephropathy (搜索) emerged as a major therapeutic focus with accelerated approval of atrasentan and positive phase 3 results for telitacicept and sibeprenlimab, demonstrating the transition from supportive care to targeted, disease-modifying strategies.
The CONFIDENCE trial showed that simultaneous initiation of finerenone and SGLT2 (搜索) inhibitors was safe and effective in chronic kidney disease (搜索) with type 2 diabetes (搜索), supporting proactive combination therapy over stepwise treatment escalation.
Nephrology experienced a transformative year in 2025, with multiple FDA approvals and late-stage clinical trial successes expanding treatment options across chronic kidney disease (搜索) (CKD), IgA nephropathy (搜索) (IgAN), lupus nephritis (搜索), and C3 glomerulopathy (搜索) (C3G). These developments reinforced nephrology as a rapidly evolving therapeutic field, with growing integration of precision-driven, mechanism-based therapies.
FDA Approvals Drive Therapeutic Innovation
The FDA's approval of semaglutide (Ozempic) to reduce the risk of kidney disease worsening, end-stage kidney disease (搜索) (ESKD), and cardiovascular death in adults with type 2 diabetes (搜索) and CKD marked a significant milestone in cardio-renal integration. The decision was supported by the phase 3b FLOW trial, which demonstrated a 24% relative risk reduction compared with placebo when added to standard therapy.
Atrasentan received accelerated approval on April (搜索) 2, 2025, as the first selective endothelin A receptor (搜索) antagonist approved to reduce proteinuria in adults with primary IgAN at risk of rapid progression. The approval did not require a REMS, reflecting regulatory confidence in proteinuria as a surrogate endpoint and potentially broadening targeted therapy use in IgAN.
Pegcetacoplan was approved on July 28, 2025, for adolescents and adults with C3G or immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), including post-transplant recurrence. The approval followed positive 26-week VALIANT trial results, the largest single trial in these rare diseases, marking a durable, precision-focused treatment strategy.
IgA Nephropathy Emerges as Therapeutic Hotspot
IgAN dominated the headlines in 2025, reflecting a shift from supportive care to targeted, disease-modifying strategies. The FDA's accelerated approval of atrasentan confirmed acceptance of proteinuria-based endpoints, while phase 3 data for telitacicept and sibeprenlimab, alongside interim ORIGIN-3 results for atacicept, highlighted multiple mechanisms, including endothelin A receptor (搜索) antagonism and BAFF (搜索)/APRIL (搜索) inhibition.
Telitacicept, a B-cell modulating biologic, achieved a -58.9% change in 24-hour urine protein-to-creatinine ratio versus -8.8% for placebo, with a favorable safety profile. These results highlight the potential of telitacicept to provide a targeted, disease-modifying approach in IgAN.
Interim analysis of sibeprenlimab showed a 51.2% reduction in proteinuria at 9 months versus placebo. FDA BLA acceptance in May anticipates a potential approval by November 28, 2025, introducing APRIL (搜索)-targeted treatment for IgAN.
Atacicept, a dual BAFF (搜索)/APRIL (搜索) inhibitor, reduced Gd-IgA1 by 68.3%, resolved dipstick hematuria in 81% of patients, and reduced UACR by 47.3% in interim ORIGIN-3 results, providing a precision approach that addresses underlying pathogenic mechanisms.
Combination Therapy Gains Momentum in CKD
The CONFIDENCE trial demonstrated that simultaneous initiation of finerenone (Kerendia) and empagliflozin (Jardiance) was well-tolerated and produced greater reductions in UACR than either drug alone in CKD with type 2 diabetes (搜索). These findings support early, proactive combination therapy, which could redefine standard CKD care by emphasizing simultaneous cardiometabolic intervention rather than stepwise escalation.
Transplant Innovation Advances
The FDA cleared United Therapeutics (搜索)' IND application on February 3, 2025, to study UKidney™, derived from a 10 gene-edited source pig. The EXPAND trial began in November 2025 at NYU Langone Health with an initial 6-patient cohort, expanding to 50 participants to support a future Biologics License Application. This milestone represents a translational step toward expanding transplant options and may alleviate organ shortages for patients with ESKD.
Phase 2 BESTOW data suggest tegoprubart provides comparable eGFR improvements to tacrolimus but with a superior safety profile, including fewer metabolic and neurologic adverse events. These findings support further evaluation of calcineurin inhibitor–sparing regimens, which could improve long-term graft survival and patient quality of life.
Pediatric Treatment Options Expand
The FDA approved a 200 mg/mL autoinjector of belimumab on June 24, 2025, for children ≥5 years with active lupus nephritis (搜索), complementing the existing approval for pediatric systemic lupus erythematosus. This subcutaneous option allows at-home administration, which may increase adherence and reduce clinic visits, improving real-world disease management for pediatric patients.
Technological Innovation in Critical Care
FIZE Medical (搜索) and Asahi Kasei Medical (搜索) signed an exclusive distribution agreement to bring continuous, real-time digital urine-output monitoring into Japanese ICUs. The FIZE kUO system transforms urine output into a continuously measured, analyzed digital parameter—a "vital sign" for the kidneys—allowing ICU teams to better assess kidney function, support hemodynamic stability, and improve outcomes for critically ill patients.
"Maintaining hemodynamic stability in critically ill patients is an ongoing challenge in intensive care," said Dror Zerem, chief executive officer of FIZE Medical (搜索). "Our collaboration aims to provide clinicians with continuous, actionable insight to support better fluid management and improve patient outcomes."
The year 2025 was pivotal for nephrology, advancing precision-driven, mechanism-based care, supported by regulatory momentum, late-stage trial success, and increasing cardiometabolic integration. These advances signal a move toward therapy tailored to disease biology rather than uniform immunosuppression, positioning nephrology at the forefront of personalized medicine.